EDITOR’S CHOICE
The association of the neutrophil–lymphocyte ratio with the presence of minimal residual disease and outcome in patients with stage II colon cancer treated with surgery alone, by Murray et al
First published: 19 April 2021
No abstract is available for this article.
REFERENCES
- 1Murray NP, Villalon R, Orrego S, Guzman E. The association of the neutrophil-lymphocyte ratio with the presence of minimal residual disease and outcome in patients with Stage II colon cancer treated with surgery alone. Colorectal Dis. 2020; 23: 805–813.
- 2Mallappa S, Sinha A, Gupta S, Chadwick SJ. Preoperative neutrophil to lymphocyte ratio >5 is a prognostic factor for recurrent colorectal cancer. Colorectal Dis. 2013; 15: 323–8.
- 3Karoui M, Rullier A, Luciani A, Bonnetain F, Auriault ML, Sarran A, et al. Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial–the PRODIGE 22–ECKINOXE trial. BMC Cancer. 2015; 15: 511.
- 4 FOxTROT Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol. 2012; 13: 1152–60.
